Liminal BioSciences, Inc.
(Toronto Stock Exchange : LMNL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.96%58.190.0%$1899.37m
REGNRegeneron Pharmaceuticals, Inc. -0.26%597.002.5%$1174.48m
GILDGilead Sciences, Inc. -1.02%76.751.0%$975.82m
AMGNAmgen, Inc. 2.17%225.671.3%$660.44m
NVAXNovavax, Inc. 3.67%46.30102.0%$655.72m
VRTXVertex Pharmaceuticals, Inc. -2.61%265.691.9%$544.78m
ILMNIllumina, Inc. -1.20%354.113.5%$388.06m
BIIBBiogen, Inc. 2.36%306.721.6%$378.26m
SRNESorrento Therapeutics, Inc. 6.74%4.121.8%$269.11m
ALXNAlexion Pharmaceuticals, Inc. 1.35%115.212.0%$241.70m
SGENSeattle Genetics, Inc. -1.36%148.396.1%$223.95m
AAgilent Technologies, Inc. -0.83%90.381.6%$215.81m
BMRNBioMarin Pharmaceutical, Inc. -1.59%105.804.3%$184.97m
SRPTSarepta Therapeutics, Inc. 2.06%147.9913.9%$156.63m
INCYIncyte Corp. -0.31%93.512.5%$153.41m

Company Profile

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.